CDK4 and neoplasm: Inhibition of miR-191 increase PLCD1, and then decrease β-catenin, MMP-9, C-myc, N-cadherin, CDK4 and PCNA, ultimately leading to the decrease of proliferation, migration and invasion of OSCC cells, thus exerting anti-tumor effects.